Expression Analysis, a provider of microarray and processing services for drug clinical trials, will work with the Immune Tolerance Network, providing its microarray facility, the company said Tuesday.

The Immune Tolerance Network (ITN) is a collaborative research initiative that includes scientists from around the globe. It hopes to accelerate drug trials for treatment of a wide variety of afflictions and medical treatments.

Expression Analysis technology is used in gene-expression, genotyping and gene resequencing.

The company said it would work with the network over at least the next 20 months in processing clinical trial samples. Terms of the agreement were not disclosed.

“The ITN faces numerous challenges in the collection and analysis of microarray data due to its multi-trial environment and diverse research platform,” said Vicki Seyfert, ITN executive director of tolerance assays and data analysis. “We are looking forward to working with the team at Expression Analysis to help us meet these challenges.”

Targets for study include transplants, autoimmune diseases, allergies and asthma.

“The ITN is planning, developing and operating several clinical trials, and our involvement in these studies will provide it with exceptional genomic data developed in a regulatory-compliant (GLP) environment,” said Expression Analysis Chief Executive Officer Steve McPhail said in a statement.

Expression Analysis:

Immune Tolerance Network: